Bernd Brust has resigned as the president of molecular medicine at Life Technologies "in order to pursue other opportunities," the company said in a filing with the US Securities and Exchange Commission this week. Brust has led the molecular medicine business unit since January, when it was created to help the company transition to next-gen sequencing in the clinic. He previously was Life Tech's president of commercial operations. Life Tech said that Brust will continue to serve as a consultant through Dec. 31 "to assist the company with various endeavors."
People in the News: Bernd Brust
Nov 02, 2011